Department of Maxillo-Facial Surgery, "Sapienza" University, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2012 Jul;16(7):952-7.
Osteonecrosis of the jaw (ONJ) is an unremitting adverse outcome associated with bisphosphonate therapy, primarily intravenously administered, in patients with bone metastases from solid tumors, multiple myeloma and osteometabolic diseases. From 2003 many cases of bisphosphonates related osteonecrosis of the jaw (BRONJ) have been reported in literature. Sunititnib is a novel anticancer agent used in gastrointestinal cancers and renal cancers resistant to imatinib. Recent reports describe the onset of ONJ in patients treated with both sunitinib and bisphosponates. A case of osteonecrosis of the jaw related to sunitinib, without association of bisphosphonate (BP) medications has been recently reported. A recent hypothesis suggests that antiangiogenic drugs such as sunitinib could cause ONJ even without the association with BPs. We describe a case of two patients affected by renal carcinoma under BP and sunitinib medication who developed stage III bisphosphonates-related osteonecrosis of the jaw (BRONJ).
颌骨骨坏死（ONJ）是一种与双膦酸盐治疗相关的持续不良后果，主要是静脉内给药，用于治疗来自实体瘤、多发性骨髓瘤和骨代谢疾病的骨转移患者。自 2003 年以来，文献中已有许多与双膦酸盐相关的颌骨骨坏死（BRONJ）病例报告。舒尼替尼是一种新型抗癌药物，用于治疗对伊马替尼耐药的胃肠道癌和肾癌。最近的报告描述了在接受舒尼替尼和双膦酸盐治疗的患者中发生 ONJ 的情况。最近有报道称，一例与舒尼替尼相关的颌骨骨坏死与双膦酸盐（BP）药物无关。最近的一个假设表明，即使没有与 BP 联合使用，抗血管生成药物如舒尼替尼也可能导致 ONJ。我们描述了两例接受 BP 和舒尼替尼治疗的肾癌患者的病例，他们发生了 III 期与双膦酸盐相关的颌骨骨坏死（BRONJ）。
